Targeting leptin, therefore, appears a rational approach to anti‐MM therapy and in the solid cancer arena this has garnered some interest, although a trial of metformin in breast cancer as a leptin‐reducing metabolic agent was unsuccessful.97 Here, LEP is linked to breast carcinoma.